Deciphera Pharmaceuticals, Inc.
deciphera.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 10, 2024. Its latest SEC filing is a SC 13G/A from Nov 14, 2024.
10-Q for Q1 FY2024, filed May 10, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells QINLOCK, a cancer medicine, through specialty distributors and pharmacies, and develops drug candidates for cancer treatment.
10-K for FY2023, filed Feb 7, 2024We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of…View ↗
In addition to QINLOCK, our platform also enabled the discovery and development of vimseltinib, our inhibitor of the colony stimulating…View ↗
The Company primarily sells QINLOCK through specialty distributors and specialty pharmacies. The Company recognized revenues from two…View ↗
How Did They Make Money?
Most revenue comes from QINLOCK product sales to specialty distributors and pharmacies, counted when the product is delivered. In Greater China, Zai pays royalties as sales occur and may owe development and commercial milestone payments under its license.
10-K for FY2023, filed Feb 7, 2024The Company recognizes product revenues, net of variable consideration related to certain allowances and accruals, when the customer takes…View ↗
The Company primarily sells QINLOCK through specialty distributors and specialty pharmacies. The Company recognized revenues from two…View ↗
The Zai License Agreement also includes sales-based royalties for the license of intellectual property, including milestone payments based…View ↗
Pursuant to the terms of the Zai License Agreement, the Company received an upfront cash payment of $20.0 million and three development…View ↗
$163.4M
-
10-K for FY2023, filed Feb 7, 2024
$163.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenues, net
Sold outright
10-K for FY2023, filed Feb 7, 2024 |
97%
FY2020: 94%
|
Product Revenues, net, FY2023
$159.1M Sources
|
Sold outright |
|
Collaboration Arrangement
Licensed
|
2.6%
FY2020: 6.2%
|
Collaboration Arrangement, FY2023
$4.3M Sources
|
Licensed |
Who Were Their Customers?
The company primarily sells QINLOCK through specialty distributors and specialty pharmacies.
10-K for FY2023, filed Feb 7, 2024The Company primarily sells QINLOCK through specialty distributors and specialty pharmacies. The Company recognized revenues from two…View ↗
How Were They Changing?
10-Q for Q1 FY2024, filed May 10, 2024
Open tableView ↗
-
Jun 11, 2024
Ono completed its acquisition of Deciphera
Deciphera became a wholly owned Ono subsidiary; its shares will no longer be listed on Nasdaq.
Sources
8-K, filed Jun 11, 2024
The aggregate consideration paid by Merger Sub in the Offer and the Merger to acquire shares of Company Common Stock was approximately $2.4…View ↗
-
Apr 29, 2024
Deciphera agreed to be acquired by Ono
The agreement set a cash offer to acquire all company shares, followed by a merger.
Sources
8-K, filed Apr 29, 2024
On April 29, 2024, Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Deciphera”), Ono Pharmaceutical Co., Ltd., a…View ↗
Grew. Revenue grew 6.5x in 4 years, from $25M in FY2019 to $163.4M in FY2023, about 60% a year.
European commercialization
The older report describes preparing for a possible European launch; the latest describes direct commercial efforts, launches in Germany and Italy, and a paid access program in France.
10-K for FY2020, filed Feb 9, 2021 10-K for FY2023, filed Feb 7, 2024In October 2020, a marketing authorisation application (EU MAA) for QINLOCK in fourth-line GIST was accepted for review by the European…View ↗
Following QINLOCK’s EC approval in fourth-line GIST in November 2021, we have focused our direct commercial efforts in key European…View ↗
Who Did They Compete With?
Competes with Blueprint, Novartis, Pfizer, Bayer, Arog, Cogent, IDRx, Daiichi, SynOx, HutchMed, Erasca, Txinno, Ailon, Day One, Jazz Pharma, Roche, Kinnate, Black Diamond, BeiGene, and Verastem
10-K for FY2023, filed Feb 7, 2024With respect to QINLOCK, there are a number of large pharmaceutical companies and biotechnology companies marketing small molecule drugs or…View ↗
Loading...
